Protein phosphatase PP5 controls bone mass and the negative effects of rosiglitazone on bone through reciprocal regulation of PPARγ (peroxisome proliferator-activated receptor γ) and RUNX2 (runt-related transcription factor 2).

Autor: Stechschulte LA, Ge C, Hinds TD Jr, Sanchez ER, Franceschi RT, Lecka-Czernik B
Jazyk: angličtina
Zdroj: The Journal of biological chemistry [J Biol Chem] 2018 May 25; Vol. 293 (21), pp. 8314.
DOI: 10.1074/jbc.W118.003815
Databáze: MEDLINE